Urinary prostate-specific antigen and microseminoprotein-beta levels in men with and without prostate cancer: A prospective cohort study.
Journal
Indian journal of urology : IJU : journal of the Urological Society of India
ISSN: 0970-1591
Titre abrégé: Indian J Urol
Pays: India
ID NLM: 8510441
Informations de publication
Date de publication:
Historique:
entrez:
28
1
2020
pubmed:
28
1
2020
medline:
28
1
2020
Statut:
ppublish
Résumé
The role of urinary proteomics in the diagnosis of prostate cancer (PCa) is undefined. Levels of urinary biomarkers such as prostate-specific antigen (PSA) and microseminoprotein-beta (MSMB) may differ between men with and without PCa. We tested this hypothesis using urine samples before and after digital rectal examination (DRE) in men with an indication for prostate biopsy. In an institutional ethics committee approved prospective cohort study, men with elevated PSA or a nodule on DRE underwent a pre- and post-DRE urine sample examination for urinary PSA and MSMB levels. Levels were compared between men who had PCa diagnosed on biopsy (Group A) and those with a negative biopsy (Group B). Seventy-seven patients were recruited of whom 32 had PCa (Group A) and 45 had no cancer (Group B) on biopsy. The median (interquartile range) serum PSA was 49.6 (0.2-254) ng/ml. The median urine PSA (29.5 vs. 26.4 mg/dl) and MSMB (1.7 vs. 2.4 mg/dl) were similar in both groups at baseline. However, post-DRE, both these metabolites rose in Group B but not in Group A, resulting in significantly higher post-to-pre values in Group B versus Group A. The post-DRE urine PSA/MSMB ratio was also significantly different between the groups. Urinary PSA and MSMB rose significantly after DRE only in men without PCa. Post-DRE urine PSA, MSMB, and PSA/MSMB ratio can differentiate PCa from benign pathology in men with an indication for prostate biopsy.
Identifiants
pubmed: 31983827
doi: 10.4103/iju.IJU_202_19
pii: IJU-36-50
pmc: PMC6961425
doi:
Types de publication
Journal Article
Langues
eng
Pagination
50-55Informations de copyright
Copyright: © 2020 Indian Journal of Urology.
Déclaration de conflit d'intérêts
Conflicts of Interest: There are no conflicts of interest.
Références
J Urol. 1993 Apr;149(4):783-6
pubmed: 7681118
Eur Radiol. 2014 Feb;24(2):344-52
pubmed: 24196383
Eur J Cancer. 2010 Mar;46(4):765-81
pubmed: 20116997
Arch Intern Med. 1995 Feb 27;155(4):389-92
pubmed: 7531426
Crit Rev Oncol Hematol. 2010 Jan;73(1):10-22
pubmed: 19328712
J Proteomics. 2009 Aug 20;72(6):907-17
pubmed: 19457353
Eur Urol. 2014 Jun;65(6):1069-75
pubmed: 24411283
J Urol. 1992 Jul;148(1):83-6
pubmed: 1377290
Oncotarget. 2017 Apr 25;8(17):28494-28501
pubmed: 28212531
J Urol. 1994 May;151(5):1283-90
pubmed: 7512659
Urology. 1997 Nov;50(5):715-21
pubmed: 9372881
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Springerplus. 2015 Jul 28;4:380
pubmed: 26240778
South Med J. 1994 Jul;87(7):720-3
pubmed: 7517580
Eur Urol. 2011 May;59(5):823-31
pubmed: 21196075
Urology. 2005 Mar;65(3):533-7
pubmed: 15780371
N Engl J Med. 1985 Feb 7;312(6):338-43
pubmed: 3881667
Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2639-46
pubmed: 20736317
Can Urol Assoc J. 2007 Nov;1(4):377-81
pubmed: 18542821
Turk J Urol. 2013 Mar;39(1):6-11
pubmed: 26328070
Acta Oncol. 2011 Jun;50 Suppl 1:25-38
pubmed: 21604938
N Engl J Med. 1991 Apr 25;324(17):1156-61
pubmed: 1707140
PLoS One. 2010 Oct 13;5(10):e13363
pubmed: 20967219
Nat Rev Urol. 2010 Feb;7(2):101-9
pubmed: 20065953